Termination of recent-onset atrial fibrillation/flutter in the emergency department: A sequential approach with intravenous ibutilide and external electrical cardioversion

Resuscitation

Volumn 45, Issue 3, 2000, Pages 181-187

  Domanovits, Hans ^a   Schillinger, Martin ^a   Thoennissen, Jana ^a   Nikfardjam, Mariam ^a   Janata, Karin ^a   Brunner, Martin ^b   Laggner, Anton N ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atrial fibrillation flutter; Electrical cardioversion; Emergency department; Intravenous ibutilide; Safety

Indexed keywords

IBUTILIDE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMODYNAMICS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0034254041     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(00)00180-5     Document Type: Article

References (37)

1. Anderson JL. Acute treatment of atrial fibrillation and flutter. Am J Cardiol 1996;78(Suppl 8A): 17-21.
2. Camm AJ, Obel OA. Epidemiology and mechanism of atrial fibrillation and flutter. Am J Cardiol 1996;78(Suppl 8A):3-11.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of atrial fibrillation: the Framingham study. New Engl J Med 1982;306:1018-22.
4. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7.
5. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol 1992;19:41A.
6. Connors S, Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol 1997;13(Suppl A):19A-24A.
7. Mulcahy B, Coates WC, Henneman PL, Lewis RJ. New onset atrial fibrillation: when is admission medically justified? Acad Emerg Med 1996;3(2):114-9.
8. Friedman HZ, Goldberg SF, Bonema JD, Cragg DR, Hauser AM. Acute complications associated with new onset atrial fibrillation. Am J Cardiol 1991;3:114-9.
9. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. J Am Med Assoc 1992;268:2171-302.
10. Falk RH, Podrid PJ. Electrical cardioversion of atrial fibrillation. In: Falk RH, Podrid PJ, editors. Atrial Fibrillation. Mechanisms and Management. New York, NY: Raven Press, 1992:181-95.
11. Suttorp MJ, Singma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989;63:693-6.
12. Donovan KD, Cobb DJ, Coombs LJ, Lee K-Y, Weekes JW, Murdock CJ, Clarke GM. Revision of recent-onset atrial fibrillation to sinus by intravenous flecainide. Am J Cardiol 1991;67:137-41.
13. Fenster P, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide. Am Heart J 1983;106:501-4.
14. Chapman MJ, Moran JL, O'Fathartaigh ML, Peisach AR, Cunningham DM. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med 1993;19:48-52.
15. Fujiki A, Yoshida S, Tani M, Inoue H. Efficacy of class I antiarrhythmic drugs in converting atrial fibrillation unassociated with organic heart disease and their relation to atrial electrophysiologic characteristics. Am J Cardiol 1994;74:282-3.
16. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-31.
17. Capucci A, Villani GQ. Propafenone oral loading dose plus digitalis in converting atrial fibrillation to sinus rhythm: a placebo controlled multicenter trial. Circulation 1995;92:1-775.
18. Sung RJ, Tan HL, Karagounis L, Hanyok JJ, Falk R, Platia E, Des G, Hardy LA. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo controlled study. Am Heart J 1995;129:739-48.
19. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhytmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Circulation 1997;96:4298-306.
20. Ellenbogen KA, Stambler BS, Wood MA, Saager PT, Wesley RC, Meissner MD, Zoble RG, Wakefield RK, Perry KT, VanderLugt JT. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
21. Ellenbogen KA, Clemo HF, Stambler BS, Wood MA, VanderLugt JT. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996;78(Suppl 8A):42-5.
22. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter and fibrillation. Circulation 1996;94:1613-21.
23. Murray KT. Ibutilide. Circulation 1998;97:493-7.
24. Volgman AS, Carberry PA, Stambler BS, et al. Conversion efficacy and safety of intravenous ibutilide and compared with intravenous procainamid in patients with atrial flutter or fibrillation. Am J Cardiol 1998;31:1414-9.
25. Buchanan LV, Turcotte VM, Kabell GG, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993;33:10-4.
26. Nabih MA, Prcevski P, Fromm BS, Lavine SJ, Elnabtity M, Munir A, Steinmann RT, Meissner MD, Lehmann MH. Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolisation. PACE 1993;16:1975-83.
27. Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk L, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJJ. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 1998;79:568-75.
28. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78(Suppl 8A):12-6.
29. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Kimberly TP. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart J 1998;136:632-42.
30. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996;78(Suppl 8A):46-52.
31. Stambler BS, Beckman KJ, Kadish AH, Camm JA, Ellenbogen KA, Perry KT, VanderLugt JT. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997;80:458-63.
32. Van Gelder IC, Brugemann J, Crijins HJ. Current treatment recommendations in antiarrhythmic therapy. Drugs 1998;55:331-46.
33. Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996;78:41-53.
34. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger A, Morady F. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. New Engl J Med 1999;340:1849-54.
35. Domanovits H, Paulis M, Nikfardjam M, Holzer M, Stühlinger HG, Hirschl MM, Laggner AN. Sustained ventricular tachycardia in the emergency department. Resuscitation 1999;42:19-25.
36. Wesley RC, Farkhani F, Morgan D, Zimmermann D. Ibutilide: enhanced defibrillation via plateau sodium current activation. Am J Physiol 1993;264:H1269-74.
37. Bjerkelund O, Orning OM. An evaluation of DC shock treatment of atrial arrhythmias: immediate results and complications in 437 patients with long term results in the first 290 of these. Acta Med Scand 1968;184:481-91.